Speciality Medicines Ltd (SPML)

About

Speciality Medicines Ltd operates in pharmaceuticals, a segment of India's healthcare sector. With a market cap of ₹145.64 Cr, it is small-scale relative to major competitors. Limited public disclosure of operations, financials, and strategy restricts assessment of product portfolio, market positioning, and growth trajectory.

Face value: ₹10

Market cap

₹138 Cr

P/E

10.6×

P/B

—

Dividend yield

0%

ROE

—

ROCE

—

Debt / equity

—

OPM

18.2%

EPS (TTM)

₹14.8

Book value

—

52-week high

—

52-week low

—

Key insights

Company research notes and source-linked reviews

Key risks

Most financial metrics unavailable (ROE n/a, PE n/a, OPM n/a, D/E n/a) — cannot assess profitability, valuation, or financial leverage; verify financial health and sustainability
Stock volatility from 52-week range ₹125.9–₹363.05 (current ₹165.5) indicates business or valuation uncertainty — verify operational stability and drivers of price movements
Minimal institutional ownership (FII 0.24%, DII 0%) may reflect investor caution or market neglect — verify whether reflects genuine risk or data gap
Specialty pharma faces pricing regulation and intense competition in India — verify regulatory compliance, margin sustainability, and competitive positioning

Generated analysis · source review pending

Growth drivers

Market cap of ₹145.64 Cr is modest, providing scope for organic expansion and scale-up — verify capex plans, revenue trajectory, and strategic initiatives
Company operates in specialty medicines, a segment with distinct market dynamics within pharmaceuticals — verify operating margins, product differentiation, and therapeutic focus
Stock recovered from 52-week low of ₹125.9 to current ₹165.5, suggesting business stabilization or investor re-rating — verify underlying drivers and operational performance

Generated analysis · source review pending

119 historical price candles were omitted because the exchange source has not been verified.

₹156.5-0.9%1Y

Quick read

rule-based

Pros

+Comfortable interest coverage of 10.9×

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

76/100

Business quality: 57
Valuation: 95

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2026
Revenue	75
COGS	54
Gross profit	21
	7
Operating profit (EBITDA)	14
OPM %	18.2%
Depreciation	0
Interest	1
	1
Profit before tax	13
Tax	-0
Tax %	-0.1%
PAT	13
PAT margin %	17.3%
EPS (₹)	20.1

₹ Cr	Mar 2026
Equity capital	—
Reserves	—
Borrowings	—
	95
Total equity & liabilities	95
Fixed assets	2
CWIP	—
Investments	0
	93
Total assets	95

₹ Cr	Mar 2026
	-1
	-3
	28
Net cash flow	24
Free cash flow	-1
CFO / Operating profit %	-9.4%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2026
Margins
Gross margin %	28.1%
EBITDA margin %	18.2%
EBIT margin %	17.9%
PAT margin %	17.3%
Working capital
Receivable days	—
Inventory days	191
Payable days	—
NWC days	—
Leverage
Current ratio	4.72
Debt to EBITDA	—
Debt to equity	—
Interest coverage	10.9
Asset turnover	0.79
Return ratios
Return on assets %	13.7%
Return on capital employed %	18.8%
Return on equity %	—

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Dec 2025	Mar 2026
	43.43%	43.43%
	0.24%	0.24%
DII	0%	0%
Government	0%	0%
	56.33%	56.33%
No. of shareholders	757	757

Promoter holding up 0 percentage points since Dec 2025.

Mr. Parth GoyaniDirector
Mr. Sumit GoyaniDirector
Mr. Bhaveshkumar Ashokbhai SavaniDirector
Mr. Chandresh M UnagarDirector
Mrs. Archana Madhav BhayaniDirector
Anita KumawatCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Speciality Medicines Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

7

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

No events on record

Corporate actions, results dates and filings will appear here once ingested.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

7 announcementsExport CSV

28 Sept 2026, 4:10 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

28 Sept 2026, 3:24 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

28 Sept 2026, 12:32 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

5 Sept 2026, 2:50 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

3 Sept 2026, 7:45 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

3 Sept 2026, 7:42 pmAGM/EGM

Notice Of 5Th Annual General Meeting

EGM PDF

3 Sept 2026, 3:50 pmOthers

Board Meeting Outcome for Outcome Of Board Meeting Held On September 03, 2026

Outcome without intimation PDF

Date	Category	Subject	Filing
28 Sept 2026, 4:10 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
28 Sept 2026, 3:24 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Loading announcements…

Speciality Medicines Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

No events on record

Announcements

Ratio timeline

Not in the F&O segment

Quarterly record

Board and management

No fund holdings on record

No events on record

Announcements

Profit & loss

Balance sheet

Cash flow